 SAN JOSE, Calif., Dec. 14, 2020 GLOBE NEWSWIRE -- AnPac Bio-Medical Science Co., Ltd. AnPac Bio, the Company or we ANPC, a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it has made significant progress in detecting pre-cancer diseases. This development was made via novel sensor design, sensor fabrication, detection process, signal collection, signal processing and proprietary algorithms, which has been validated in both multi-year retrospective and prospective, large sample and population studies. The Company recently completed a prospective large population screening of over 110,000 individuals and over 150,000 samples throughout this study with some individuals tested multiple times over the years using AnPac Bios Cancer Differentiation Analysis CDA technology. The follow-up study involved over 13,000 individuals assessed with high cancer risk, medium cancer risk and low cancer risk using AnPac Bios CDA technology. 